U.S. markets closed

BiondVax Pharmaceuticals Ltd. (BVXV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9200-0.2900 (-9.03%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close3.2100
Open3.1500
Bid2.9300 x 3100
Ask2.9300 x 1400
Day's Range2.9100 - 3.2200
52 Week Range2.2800 - 49.8960
Volume802,106
Avg. Volume734,246
Market Cap41.85M
Beta (5Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-2.2960
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
Inf% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update
    PR Newswire

    BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its first quarter financial results for the quarter ended March 31, 2021. A summary is included in the tables below.

  • BiondVax Pharmaceuticals Ltd. (BVXV): Hedge Funds Are Snapping Up
    Insider Monkey

    BiondVax Pharmaceuticals Ltd. (BVXV): Hedge Funds Are Snapping Up

    Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

  • BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
    PR Newswire

    BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2020 and provided a business update.